The single-target molecular targeted drugs, EGFR-TKI inhibitors, Erysart and Troche, have opened new avenues of treatment for advanced non-small cell lung cancer, from which many patients have benefited, but the next step of treatment after treatment failure has become a dilemma for doctors and patients alike. Multi-level, cross-inhibition of the different signaling pathways that induce malignancy can inhibit tumor growth more effectively. Multi-target drugs can inhibit the function of VEGF, PDGF, FLT and KIT, which have both anti-tumor and anti-angiogenic activities, thus becoming another powerful weapon for us to overcome the disease. Patient Ma XX, ID number 10156138, female, 42 years old, postoperative left lung adenocarcinoma, bilateral lung metastases and multiple bone metastases. Her previous chemotherapy and single-target drug treatment with Erythroxel and Troche had unsatisfactory results. Multi-targeted drugs were given in the fifth line, and the metastases in both lungs largely disappeared after 4 weeks of treatment, and the maintenance treatment has been maintained for more than 8 months now, with stable disease and tolerable adverse effects, and the patient is now living a normal life.